Clinical Trial: An Open-Label. vulticenter, Phase l Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and PreliminaryEficacy of PZH2113 Capsules in Subjects with Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma, PredominantlyDiffuse Large B-Cell Lymphoma (China)

China, Oct. 19 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'An Open-Label. vulticenter, Phase l Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and PreliminaryEficacy of PZH2113 Capsules in Subjects with Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma, PredominantlyDiffuse Large B-Cell Lymphoma'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600134590

Registration Time: 2026/10/16

Type: Interventional study

Primary Sponsor: Sun Yat-sen University Cancer Center

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=323804

Published by HT Digital Content Services with permission from Health Daily D...